HIV Infections: all 4,340 studies

Page 8 of 44. Open to participants first (240), then studies with results posted, then the rest; newest registration first within each.

• Trial of Ibudilast for Methamphetamine DependenceCompletedNCT01860807Phase 2Results posted
• HIV Non-Occupational Post-Exposure ProphylaxisCompletedNCT01855867Phase 4Results posted
• Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed ChildrenCompletedNCT01854775Phase 2/3Results posted
• Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV InfectionTerminatedNCT01854762Phase 2/3Results posted
• Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIVCompletedNCT01852942Phase 2Results posted
• Living Well Project for Persons With AIDSCompletedNCT01848483Not applicableResults posted
• Brief Intervention for Rural Women at High Risk for HIV/HCVCompletedNCT01840722Not applicableResults posted
• Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With CobicistatCompletedNCT01837719Phase 1Results posted
• Lactoferrin Treatment in HIV PatientsCompletedNCT01830595Phase 2Results posted
• Evaluating the Safety and Pharmacokinetics of Raltegravir in InfantsCompletedNCT01828073Results posted
• Co-receptor Tropism Determination of HIV-1 Subtype A Spread in the Russian Federation Using V3-based Genotyping ToolsCompletedNCT01823614Results posted
• Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency VirusCompletedNCT01822522Phase 1Results posted
• Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal ImpairmentCompletedNCT01818596Phase 3Results posted
• Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsCompletedNCT01815736Phase 3Results posted
• Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)TerminatedNCT01814722Results posted
• Study to Evaluate a HIV Drug for the Treatment of HIV InfectionCompletedNCT01803074Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsCompletedNCT01797445Phase 3Results posted
• Pilot Study of Bydureon to Treat Diabetes in HIV-infected AdultsTerminatedNCT01791465Phase 4Results posted
• Adherence Support Intervention for Persons Living With HIV/AIDS (PLWHA) on Antiretroviral Therapy (ART) in EstoniaCompletedNCT01789138Not applicableResults posted
• Music for Health ProjectCompletedNCT01786148Not applicableResults posted
• A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected AdultsCompletedNCT01783678Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsCompletedNCT01780506Phase 3Results posted
• An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure ProphylaxisCompletedNCT01772823Phase 2Results posted
• Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin LymphomaCompletedNCT01771107Phase 1/2Results posted
• Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).CompletedNCT01769469Results posted
• An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)CompletedNCT01769456Phase 2Results posted
• Atorvastatin for HAART Suboptimal RespondersCompletedNCT01766076Phase 3Results posted
• Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cARTCompletedNCT01751646Not applicableResults posted
• Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 InfectionCompletedNCT01734850Phase 1/2Results posted
• Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV DiseaseTerminatedNCT01731691Phase 2/3Results posted
• CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)CompletedNCT01721226Not applicableResults posted
• Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in AdolescentsCompletedNCT01721109Phase 2/3Results posted
• HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /RibavirinTerminatedNCT01718301Phase 3Results posted
• A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)CompletedNCT01717287Phase 2Results posted
• A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line TreatmentCompletedNCT01709084Phase 3Results posted
• Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive WomenCompletedNCT01705574Phase 3Results posted
• Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) TabletCompletedNCT01694420Phase 3Results posted
• Integrated Care Centers to Improve HIV Outcomes in Vulnerable Indian PopulationsCompletedNCT01686750Not applicableResults posted
• Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young AdultsCompletedNCT01685372Phase 2Results posted
• Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected AdultsCompletedNCT01667731Phase 3Results posted
• Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) ProgramCompletedNCT01662336Results posted
• Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus RilpivirineCompletedNCT01641809Phase 2Results posted
• Development of Method of Fructose Identification in Urine to Detect the Viral InfectionCompletedNCT01638312Results posted
• Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) ClinicsCompletedNCT01632995Not applicableResults posted
• A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)CompletedNCT01632345Phase 2Results posted
• Clinical Trial to Reduce Drinking in Women With HIVCompletedNCT01625091Phase 3Results posted
• A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)CompletedNCT01622673Phase 1Results posted
• Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child TransmissionCompletedNCT01618305Phase 4Results posted
• Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in WomenCompletedNCT01617096Phase 3Results posted
• Metabolic Abnormalities in HIV-infected PersonsCompletedNCT01612858Phase 4Results posted
• Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical CancerCompletedNCT01590017Phase 2Results posted
• Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or ElivitegravirCompletedNCT01568892Phase 3Results posted
• D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive AdultsCompletedNCT01565850Phase 2Results posted
• HIV, Buprenorphine, and the Criminal Justice SystemCompletedNCT01550341Not applicableResults posted
• Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative WomenCompletedNCT01539226Not applicableResults posted
• Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsCompletedNCT01533259Phase 3Results posted
• Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical PracticeCompletedNCT01524900Results posted
• Vitamin D Supplementation in HIV YouthCompletedNCT01523496Phase 2/3Results posted
• Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)CompletedNCT01516970Phase 3Results posted
• Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk WomenCompletedNCT01505114Phase 2Results posted
• Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and ChildrenCompletedNCT01504841Phase 1/2Results posted
• American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical TrialCompletedNCT01500096Phase 2Results posted
• A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive SubjectsCompletedNCT01499199Phase 3Results posted
• Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT01497899Phase 2Results posted
• Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsCompletedNCT01495702Phase 3Results posted
• Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African MenCompletedNCT01490359Not applicableResults posted
• A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1CompletedNCT01479868Phase 3Results posted
• Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsCompletedNCT01475838Phase 3Results posted
• Drug Exposure Registry for GSK2248761, an Investigational NNRTICompletedNCT01458132Results posted
• Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive SubjectsCompletedNCT01449929Phase 3Results posted
• A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)CompletedNCT01449006Phase 4Results posted
• A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current TreatmentCompletedNCT01448707Phase 3Results posted
• A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIVTerminatedNCT01448486Phase 4Results posted
• Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected AdultsCompletedNCT01440569Phase 3Results posted
• Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected IndividualsCompletedNCT01433289Phase 1Results posted
• A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected PatientsCompletedNCT01391013Phase 2Results posted
• HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) InfectionsCompletedNCT01384734Phase 2Results posted
• Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)CompletedNCT01383005Results posted
• Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female VolunteersCompletedNCT01374802Phase 1Results posted
• Therapy to Elevate CD4 Counts in HIV-1 DiseaseCompletedNCT01370018Phase 2/3Results posted
• Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal ImpairmentCompletedNCT01363011Phase 3Results posted
• Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort StudyCompletedNCT01360762Phase 3Results posted
• Switch to Unboosted Atazanavir With Tenofovir StudyCompletedNCT01351740Phase 4Results posted
• Drug Drug Interaction of BI 201335 and TenofovirCompletedNCT01340196Phase 1Results posted
• Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging StrategyTerminatedNCT01338025Phase 4Results posted
• Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)CompletedNCT01335191Phase 1/2Results posted
• Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infectionCompletedNCT01328158Results posted
• A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.CompletedNCT01328041Phase 3Results posted
• The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)CompletedNCT01327651Phase 2Results posted
• A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis BCompletedNCT01327547Phase 4Results posted
• Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and AdolescentsCompletedNCT01302847Phase 1/2Results posted
• Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral TherapyCompletedNCT01295515Phase 1/2Results posted
• A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)CompletedNCT01263015Phase 3Results posted
• Improving Immunogenicity of Influenza Vaccine in HIV Infected IndividualsCompletedNCT01262846Phase 4Results posted
• Two Approaches to Routine HIV Testing in a Hospital Emergency DepartmentCompletedNCT01258582Not applicableResults posted
• Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice PopulationsCompletedNCT01246401Phase 1/2Results posted
• Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)TerminatedNCT01231555Phase 2Results posted
• A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive AdultsCompletedNCT01231516Phase 3Results posted
• Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)CompletedNCT01228318Phase 2Results posted
• A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice DailyCompletedNCT01227824Phase 3Results posted

← HIV Infections overview